CompanyHOWLNasdaqWaltham, MA

Werewolf Therapeutics, Inc.

Werewolf Therapeutics develops conditionally activated cytokine molecules (INDUKINE) designed to stimulate immune response in tumors.

SEC EDGAR ClinicalTrials.gov investors.werewolftx.com

SCHEDULE 13GSep 21Latest SEC filing

Aug 21Latest story

August 2026

Werewolf Therapeutics and Ambros Therapeutics agree to merge, plan $150M private placement

Aug 21Regulatory decisionWerewolf Therapeutics, Inc.

Werewolf Therapeutics sells preclinical platforms to EMD Serono for $28M upfront

Aug 20PartnershipWerewolf Therapeutics, Inc.WTX-124

July 2026

Werewolf posts Q2 2026 net income after Jazz deal, sets H2 update plans for WTX-124, WTX-330

Jul 31Quarterly updateJazz Pharmaceuticals Werewolf Therapeutics, Inc.